Modality
Bispecific Ab
MOA
KIF18Ai
Target
RET
Pathway
Fibrosis
EpilepsyRSV
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Oct 2030
Phase 1Current
NCT03693673
1,023 pts·Epilepsy
2017-12→2030-10·Terminated
1,023 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-194.6y awayInterim· Epilepsy
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Termina…
Catalysts
Interim
2030-10-19 · 4.6y away
Epilepsy
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03693673 | Phase 1 | Epilepsy | Terminated | 1023 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| RHH-5389 | Roche | Preclinical | RET | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET |